SHANGHAI–(BUSINESS WIRE)–Maxinovel Pharmaceuticals, Inc. presented in the 2019 AACR the head to head comparison of its orally active small molecule PD-L1 inhibitor with commercially marketed PD-L1 antibody drug Durvalumab in the human PD-L1 knock-in MC38 cell line in human PD-1 knock-in mice model [LB-018]. These two molecules demonstrated similar tumor growth inhibition (TGI) when they were tested twice. “It is very exciting to know that orally active small molecule PD-L1 inhibitor has simil

Source link